A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery

Alfredo Papa, Alessandro Armuzzi, Gianluca Andrisani, Luisa Guidi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pyoderma gangrenosum (PG) is an ulcerating noninfectious disease of the skin seen in 1-2% of patients with inflammatory bowel disease (IBD). The pathogenesis of PG has yet to be determined, but may be related to abnormal T cell responses and the production of TNF-α, a pathway also involved in IBD pathogenesis. Infliximab, a chimeric monoclonal antibody to TNF-α, is used to treat moderate to severe IBD and several case reports and studies suggest the efficacy of infliximab in the treatment of PG. The surgical approach to PG is reserved to a few selected cases. We report here the case of a patient with ulcerative colitis (UC) and PG localized on the left breast, treated with a simultaneous combined medical and surgical approach.
Original languageEnglish
Pages (from-to)421-426
Number of pages6
JournalJournal of Crohn's and Colitis
Volume7
Publication statusPublished - 2013

Keywords

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Colitis, Ulcerative
  • Combined Modality Therapy
  • Humans
  • Male
  • Pyoderma Gangrenosum
  • Skin Transplantation

Fingerprint

Dive into the research topics of 'A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery'. Together they form a unique fingerprint.

Cite this